The Department of Oncology provides comprehensive oncology treatment (radiotherapy, chemotherapy, immunotherapy, supportive treatment, and palliative care) in cancer patients with a preferred focus on breast cancer, colorectal and bronchogenic cancers. It provides care for genetically conditioned tumors and operates specialized outpatient clinics for selected groups of tumors (carcinoid, thymomas) and selected groups of patients (gerontooncology, younger patients with breast cancer). In close cooperation, he is involved in the comprehensive treatment of hematological malignancies and gynecological and orofacial tumors. It organizes and participates in the work of interdisciplinary teams to ensure adequate diagnostic, therapeutic and dispensary care for cancer patients. He is a founding member of the Comprehensive Cancer Center.

The average number of new patients per year is about 1,200. The average number of dispensarized and treated patients is 30,000.

The Department of Oncology is an internationally respected base for Phase I - III clinical trials. Clinical research is focused on breast, lung, head and neck cancers and gastrointestinal tumors. One of the main research programs of the clinic within the framework of grant solutions is the use of unconventional radiation sources in the treatment of cancer and the biomodulation of radiotherapy. The Oncology Laboratory is designed as a workplace of applied research to determine the sensitivity of tumor cells to individual anticancer drugs and to investigate molecular biological factors that affect efficacy.

As of May 1, 2021, the operation of Non-Cancer Therapy at the Oncology Clinic is terminated.